Analytica's lead product is the PeriCoach™ System - an e-health treatment system for women who suffer Stress Urinary Incontinence. This debilitating condition affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles during pregnancy, childbirth and menopause. It is estimated that by 2030, more than 5 million women in Australia alone will be affected.

PeriCoach™ comprises a novel device, web portal and smartphone app. The device is discreet and works by evaluating activity in pelvic floor muscles. This information is immediately transmitted to a smartphone. From there it can be uploaded and accessed by physicians via cloud based portal.

This novel system enables physicians to remotely determine if a woman is correctly performing pelvic floor exercises and if these are improving her condition; otherwise physicians are guided on the need for surgery.

PeriCoach™ is unique. The product has been approved in Australia with product launches expected in 2014 in Australia, Europe and the US*. The US market for incontinence pads is $5 billion pa.

Analytica is also commercialising the AutoStart™ Infusion System. This is a burette with improved safety and cost reduction features. It is targeting a $3 billion pa global market, has FDA approval and potential near term cash flow with distribution agreements.

* The PeriCoach is not yet available for sale in the US or Europe.

Investment Information

Analytica Limited (ABN 12 006 464 866) is a Brisbane-based public company listed on the Australian Stock Exchange (ASX Code: ALT). For more information, see About Us and ASX Releases.

Recent News

Announcements are also available as an RSS feed